Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bausch Health Companies Inc (BHC)

Bausch Health Companies Inc (BHC)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,509,205
  • Shares Outstanding, K 351,884
  • Annual Sales, $ 8,380 M
  • Annual Income, $ -4,148,000 K
  • 60-Month Beta 0.85
  • Price/Sales 0.88
  • Price/Cash Flow 1.70
  • Price/Book 2.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate 1.05
  • Number of Estimates 6
  • High Estimate 1.12
  • Low Estimate 1.00
  • Prior Year 1.15
  • Growth Rate Est. (year over year) -8.70%

Price Performance

See More
Period Period Low Period High Performance
1-Month
18.72 +18.43%
on 10/07/19
23.44 -5.42%
on 09/17/19
-1.20 (-5.13%)
since 09/16/19
3-Month
18.72 +18.43%
on 10/07/19
24.75 -10.42%
on 07/29/19
-1.00 (-4.32%)
since 07/16/19
52-Week
17.20 +28.90%
on 12/26/18
27.72 -20.02%
on 11/08/18
-3.75 (-14.47%)
since 10/16/18

Most Recent Stories

More News
Implied Volatility Surging for Bausch Health (BHC) Stock Options

Investors need to pay close attention to Bausch Health (BHC) stock based on the movements in the options market lately.

BHC : 22.17 (+3.89%)
Bausch Files Lawsuit Against Novartis' Sandoz, Shares Down

Bausch's (BHC) shares down on lawsuit filed against Novartis' Sandoz defending Xifaxan patents.

NVS : 87.00 (+0.35%)
INCY : 78.12 (-0.51%)
TEVA : 6.95 (-0.29%)
BHC : 22.17 (+3.89%)
Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

PFE : 36.34 (-0.44%)
FGEN : 40.30 (+3.71%)
AERI : 20.77 (+2.42%)
BHC : 22.17 (+3.89%)
Foamix Initiates Phase II Study on Acne Combination Foam

Foamix (FOMX) enrolls first patient in phase II study on its topical combination foam, FCD105, for the treatment of moderate-to-severe acne vulgaris.

FOMX : 3.09 (+3.00%)
EVOK : 0.85 (+5.81%)
RDY : 38.13 (-0.16%)
BHC : 22.17 (+3.89%)
Ardelyx Gets FDA Approval for Ibsrela As IBS-C Treatment

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela....

AGN : 170.92 (+0.45%)
IRWD : 8.93 (-1.11%)
ARDX : 4.34 (-1.59%)
BHC : 22.17 (+3.89%)
Ardelyx (ARDX) Gains on Tenapanor's Success in Pivotal Study

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

AGN : 170.92 (+0.45%)
IRWD : 8.93 (-1.11%)
ARDX : 4.34 (-1.59%)
BHC : 22.17 (+3.89%)
Is Bausch Health Cos (BHC) Outperforming Other Medical Stocks This Year?

Is (BHC) Outperforming Other Medical Stocks This Year?

BHC : 22.17 (+3.89%)
Is Bausch Health Cos (BHC) a Good Value Investor Pick?

Let's see if Bausch Health Cos (BHC) stock is a good choice for value-oriented investors right now from multiple angles.

BHC : 22.17 (+3.89%)
Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

PFE : 36.34 (-0.44%)
RHHBY : 35.7400 (-1.30%)
AERI : 20.77 (+2.42%)
BHC : 22.17 (+3.89%)
Bausch (BHC) Misses on Q2 Earnings & Sales, Raises View

Bausch (BHC) misses on both earnings and sales in the second quarter of 2019 but lifts revenue outlook on new products.

GALT : 3.86 (-1.28%)
PTLA : 27.44 (+0.05%)
BHC : 22.17 (+3.89%)
ETON : 6.12 (-3.37%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Good. Long term indicators fully support a continuation of the trend.

See More Share

Trade BHC with:

Business Summary

Bausch Health Companies Inc. develops and distributes drugs. It develops drugs for unmet medical needs in central nervous system disorders and distributes generic and branded generic drugs primarily in Latin America and Eastern Europe. Bausch Health Companies Inc., formerly known as Valeant Pharmaceuticals,...

See More

Key Turning Points

2nd Resistance Point 23.03
1st Resistance Point 22.60
Last Price 22.17
1st Support Level 21.62
2nd Support Level 21.07

See More

52-Week High 27.72
Fibonacci 61.8% 23.70
Fibonacci 50% 22.46
Last Price 22.17
Fibonacci 38.2% 21.22
52-Week Low 17.20

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar